Search Result

Results for "

systolic heart failure

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (1) Angiotensin Receptor (2) Apoptosis (1) ATP Synthase (1) Calcium Channel (3) Carbonic Anhydrase (1) Caspase (1) Drug Derivative (2) Endogenous Metabolite (4) Isotope-Labeled Compounds (1) Mineralocorticoid Receptor (4) Myosin (1) Na+/H+ Exchanger (NHE) (1) Natriuretic Peptide Receptor (NPR) (1) NO Synthase (1) Potassium Channel (1) Reference Standards (2) RXFP Receptor (1) Vasopressin Receptor (1) VEGFR (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (16) Neurological Disease (1)

By Targets:

Adrenergic Receptor (1)

Akt (1)

Angiotensin Receptor (2)

Apoptosis (1)

ATP Synthase (1)

Calcium Channel (3)

Carbonic Anhydrase (1)

Caspase (1)

Drug Derivative (2)

Endogenous Metabolite (4)

Isotope-Labeled Compounds (1)

Mineralocorticoid Receptor (4)

Myosin (1)

Na+/H+ Exchanger (NHE) (1)

Natriuretic Peptide Receptor (NPR) (1)

NO Synthase (1)

Potassium Channel (1)

Reference Standards (2)

RXFP Receptor (1)

Vasopressin Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (16)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0251

Eplerenone 5+ Cited Publications Epoxymexrenone	Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease Cancer
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-148804

Vemtoberant APD418	Adrenergic Receptor	Cardiovascular Disease
Vemtoberant is a β₃-adrenergic receptor inhibitor with a human K_i of 8.2 nM, and exhibits 400- to 600-fold selectivity over human β₁-AR and β₂-AR. Vemtoberant attenuates β₃-AR-mediated cardiac inhibition. Vemtoberant can be used for the research of systolic heart failure .

HY-149662

TMDJ-035	Calcium Channel ATP Synthase Myosin	Cardiovascular Disease
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC₅₀ of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca ²⁺ transients. TMDJ-035 decreases ATP content and intracellular Ca ²⁺ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-124873

SERCA2a activator 1	Calcium Channel	Cardiovascular Disease
SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca ²⁺-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure .

HY-B0251R

Eplerenone (Standard) 5+ Cited Publications Epoxymexrenone (Standard)	Reference Standards Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease Cancer
Eplerenone (Standard) is the analytical standard of Eplerenone. This product is intended for research and analytical applications. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-W414915

Valsartan methyl ester CGP 48933 methyl ester	Drug Derivative Angiotensin Receptor	Cardiovascular Disease Cancer
Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-18347

Conivaptan YM 087 free base	Vasopressin Receptor	Cardiovascular Disease
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .

HY-173517

NHE-1-IN-2	Na+/H+ Exchanger (NHE)	Neurological Disease
NHE-1-IN-2 (compound 7g) is a potent NHE-1 inhibitor with an IC₅₀ of 0.78 μM. NHE-1-IN-2 alleviates left ventricular systolic dysfunction in mice model of heart failure .

HY-131948

3-Chlorodiphenylamine	Potassium Channel	Cardiovascular Disease
3-Chlorodiphenylamine is a high affinity Ca ²⁺ sensitizer of cardiac muscle. 3-Chlorodiphenylamine is based on diphenylamine and binds to the isolated N-domain of cardiac troponin C (cTnC) (K_d=6 µM). 3-Chlorodiphenylamine is an excellent starting scaffold for the development of more potent Ca ²⁺-sensitizing compounds due to its small size, and can be used for systolic heart failure research .

HY-147384

CXL-1020	Calcium Channel	Cardiovascular Disease
CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca ²⁺ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure .

HY-B0251S1

Eplerenone-13C,d3 Epoxymexrenone-¹³C,d₃	Isotope-Labeled Compounds Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease Cancer
Eplerenone- ¹³C,d₃ (Epoxymexrenone- ¹³C,d₃) is ¹³C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-120321

DSR-71167	Mineralocorticoid Receptor Carbonic Anhydrase	Cardiovascular Disease
DSR-71167 is an orally active mineralocorticoid receptor (MR) antagonist with an IC₅₀ of 0.26 μM. DSR-71167 exhibits weak carbonic anhydrase (CA) inhibitory activity with an IC₅₀ of 19 μM. DSR-71167 can dose-dependently increase urinary sodium excretion in rat models and has a very low risk of hyperkalemia in potassium-loading rat models. DSR-71167 lowers systolic blood pressure in hypertensive rat models. DSR-71167 can be used for research on hypertension and heart failure .

HY-137396

6β-Hydroxy Eplerenone	Endogenous Metabolite	Cardiovascular Disease
6β-Hydroxy Eplerenone is a metabolite of Eplerenone (HY-B0251). 6β-Hydroxy Eplerenone plays an important role in the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-120257

IDN-1965	Caspase Apoptosis	Cardiovascular Disease
IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation .

HY-W414915R

Valsartan methyl ester (Standard) CGP 48933 methyl ester (Standard)	Reference Standards Drug Derivative Angiotensin Receptor	Cardiovascular Disease
Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-P992108

Efadirelaxin alfa RELAX10	RXFP Receptor Akt NO Synthase VEGFR	Cardiovascular Disease
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-P992108

Efadirelaxin alfa RELAX10	RXFP Receptor Akt NO Synthase VEGFR	Cardiovascular Disease
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0251

Eplerenone 5+ Cited Publications Epoxymexrenone	Cardiovascular Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Mineralocorticoid Receptor Endogenous Metabolite
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

Cat. No.	Product Name	Chemical Structure

HY-B0251S1

Eplerenone-13C,d3
Eplerenone- ¹³C,d₃ (Epoxymexrenone- ¹³C,d₃) is ¹³C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

Eplerenone-13C,d3

Eplerenone- ¹³C,d₃ (Epoxymexrenone- ¹³C,d₃) is ¹³C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks